Chemical Property of Citalopram
Chemical Property:
- Appearance/Colour:grease
- Melting Point:182-183 °C
- Boiling Point:428.3 °C at 760 mmHg
- PKA:pKa 9.38(H2O) (Uncertain)
- Flash Point:212.8 °C
- PSA：36.26000
- Density:1.18 g/cm3
- LogP:3.81298
- Storage Temp.:Store at RT
- Solubility.:Methanol (Slightly), Water (Slightly)
- XLogP3:3.2
- Hydrogen Bond Donor Count:0
- Hydrogen Bond Acceptor Count:4
- Rotatable Bond Count:5
- Exact Mass:324.16379146
- Heavy Atom Count:24
- Complexity:466
- Purity/Quality:
-
99% *data from raw suppliers
Citalopram, Hydrobromide Salt *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
- Recent ClinicalTrials:Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment
- Recent EU Clinical Trials:Effect of citalopram on chest pain in patients with functional chest pain
-
Description
Citalopram is a specific serotonin-uptake inhibitor useful in the treatment of depression.
In endogenous depression citalopram was reported to be as effective as amitriptyline and
mianserin, while being inferior to clomipramine in both endogenous and non-endogenous
depression.
-
Uses
scabicide antidepressant monoamine oxidase inhibitor (MAOIs)
-
Biological Functions
Citalopram (Celexa) has an elimination half-life of 35
hours and is 80% bound to plasma proteins. Of all of the
SSRIs it has the least effect on the cytochrome P450 system
and has the most favorable profile regarding
drug–drug interactions.
-
Clinical Use
SSRI antidepressant:
Depressive illness
Panic disorder
-
Drug interactions
Potentially hazardous interactions with other drugs
Analgesics: increased risk of bleeding with aspirin
and NSAIDs; risk of CNS toxicity increased with
tramadol.
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone, disopyramide and
dronedarone - avoid.
Antibacterials: possibly increased risk of ventricular
arrhythmias with IV erythromycin, moxifloxacin,
pentamidine and telithromycin.
Anticoagulants: effect of coumarins possibly
enhanced; possibly increased risk of bleeding with
dabigatran.
Antidepressants: avoid with MAOIs and
moclobemide, increased risk of toxicity; avoid with
St John’s wort; possibly enhanced serotonergic
effects with dapoxetine and duloxetine; can increase
tricyclics antidepressant concentration; increased
agitation and nausea with tryptophan; possible
increased risk of convulsions with vortioxetine.
Antiepileptics: convulsive threshold lowered.
Antihistamines: increased risk of ventricular
arrhythmias with mizolastine - avoid.
Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol; possible increased
risk of ventricular arrhythmias with chloroquine and
quinine.
Antipsychotics: possibly increased clozapine
concentration; increased risk of ventricular
arrhythmias with haloperidol and pimozide - avoid.
Antivirals: concentration possibly increased by
ritonavir.
Beta-blockers: increased risk of ventricular
arrhythmias with sotalol - avoid.
Dopaminergics: avoid with selegiline; increased risk
of CNS toxicity with rasagiline.
5 HT1
agonist: increased risk of CNS toxicity -
avoid; possibly increased risk of serotonergic effects
with naratriptan.
Linezolid: use with care, possibly increased risk of
side effects.
Lithium: increased risk of CNS effects.
Methylthioninium: risk of CNS toxicity - avoid if
possible.
